couter

300357.SZZhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Health CarePharmaceuticals

This is the year Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has to prove it can scale its allergy immunotherapy business beyond the $27.00 anchor after Q3 2026 earnings, with the next catalyst on November 25th testing the NRDL regulatory gamble and the final test in early 2027 when its pipeline results and full-year results will decide whether it’s a growth story or a cash-burning liability.

Nov 25, 2026 — NRDL & Regulatory Policy Updates
Chart by TradingView

The schedule

  • Wed25Nov

    Annual National Reimbursement Drug List (NRDL) negotiations, presenting price-cut risks against volume expansion for Wolwo's core therapies from the $29.80 level.

  • Thu18Feb

    Expected clinical trial updates for expanding the allergy immunotherapy pipeline into new indications, anchoring at the $25.00 post-NRDL level.

  • Fri26Feb

    Q3 2026 earnings report, evaluating allergy immunotherapy sales penetration and gross margin defense against the $27.00 anchor.

  • Fri28May
  • Fri27Aug

    Full-year 2026 and Q1 2027 combined earnings print, providing vital forward guidance on market share and R&D spending from a $28.50 anchor.

Past

  • Fri28Aug

    Actual outcome: Bear · $18.98 at outcome

    Stock fell 17.2% from event to outcome date, aligning with the bear trajectory.

    Q2 2026 earnings release, testing whether the recent 60.38% net income growth trajectory can be sustained despite the stock trading down to $24.65.